초록 ▼

Compositions containing a tissue plasminogen activator (t-PA), epidermal growth factor (EGF), transforming growth factor-alpha (TGFab2 surface binding glycoprotein in a suitable physiologically acceptable carrier are useful for the treatment of humans when topically and/or subcutaneously applied. Th

Compositions containing a tissue plasminogen activator (t-PA), epidermal growth factor (EGF), transforming growth factor-alpha (TGFab2 surface binding glycoprotein in a suitable physiologically acceptable carrier are useful for the treatment of humans when topically and/or subcutaneously applied. These compositions might also usefully contain or have employed in association therewith an adjuvant to aid in the transdermal transport or transfer of the compositions, particularly the active components therein, through or across the skin. Also, these compositions might also have contained therein or employed in association therewith an antiviral agent, such as an antiviral surfactant, for example, an antiviral nonionic surfactant, e.g. nonylphenoxypolyethoxy ethanol and/or human interferon, e.g. alpha-interferon. Additionally, these compositions might contain or have employed in association therewith an antitumor agent, such as tumor necrosis factor (TNF), target cell lysis factor (TCLF) and carcino-breaking factor (CBF). These compositions are useful in the treatment or healing of humans, e.g. in the treatment of viral and/or cancerous skin disorders or lesions and/or to expedite healing.

대표청구항 ▼

A composition suitable for topical or subcutaneous application to a human for the treatment of cancerous or virus-caused skin disorders consisting essentially of a physiologically acceptable carrier, an antiviral or anti-cancer effective amount of a biologically active material selected from the gro

A composition suitable for topical or subcutaneous application to a human for the treatment of cancerous or virus-caused skin disorders consisting essentially of a physiologically acceptable carrier, an antiviral or anti-cancer effective amount of a biologically active material selected from the group consisting of tissue plasminogen activator (t-PA), epidermal growth factor (EGF), transforming growth factor-alpha (TGF-ab2 surface binding protein, an effective antiviral amount of an antiviral surfactant, an effective antiviral amount of human interferon and an effective amount of an adjuvant to assist in the transdermal transport or transfer of said composition through the skin.